摘要
目的 :探讨肿瘤标志物的联合检测在肺癌诊断及鉴别诊断的临床意义。方法 :采集 14 4例有肺部疾病入院患者的血清样本 ,其中肺癌患者 94例 ,肺部良性病变患者 (BLD) 5 0例 ,用免疫放射法检测其血清CEA、CA15 3、SCC和CY2 11的含量。结果 :肿瘤患者血清CEA、CA15 3、SCC、CY2 11的阳性率分别为 38.2 0 %、5 9.30 %、2 0 .4 8%和 5 4 .95 % ,明显高于BLD组 (P <0 .0 0 1) ;非小细胞肺癌 (NSCLC)中鳞癌以CY2 11阳性率最高 ,达 88.4 6 % ,腺癌为CA15 3(73.91% ) ,小细胞肺癌 (SCLC)为CY2 11(5 2 .94 % ) ;四项标志物联合检测可将阳性率提高到 89.36 % ,特异度为 80 % ;血清CA15 3+CY2 11联合检测敏感度为84 .94 % ,特异度为 84 % ;对于不同分期 ,血清CEA、CA15 3和CY2 11含量随期别的升高而升高 ;标志物联合检测早期肿瘤诊断敏感度为 75 %。结论 :血清肿瘤标志物CEA、CA15 3、SCC和CY2 11联合检测可提高肺癌诊断的敏感度及早期诊断阳性率 ,建议联合检测方式以CA15 3和CY2 11为佳。
Objective: To study the clinic significance of tumor marker with combined assaying in the diagnosis and differential diagnosis of lung cancer. Methods: 144 serum samples collected from 144 in-patients. Among them, 94 patients were affected with lung cancer, and 50 patients were benign lung diseases (BLD). The concentration of serum CEA, CA153, SCC and CY211 was determined by immunoradiometric assay. Results: In lung cancer group, the total positive rates of CEA, CA153, SCC and CY211 are 38.20%,59.30%,20.48%,54.95%, which were significantly higher than that in BLD group ( P <0.001). Among non-small cell lung cancer (NSCLC) group, the highest positive rate in squamous cell carcinoma was CY211 (88.46%), adenocarcinoma was CA153 (73.91%), small cell lung cancer (SCLC) was CY211 (52.94%). The positive rate of combined assay with four tumor markers was raised to 89.36%, with the specificity 80%; The sensitivity of combined assay with serum CA153+CY211 in diagnosing lung cancer was 84.94%, with the specificity 84%; In the different cell-Clinical-styped lung cancer patient, the concentrations of serum CEA, CA153 and CY211 were higher in the advanced lung cancer. The sensitivity of combined assay was 75% in early lung cancer. Conclusion: The sensitivity in diagnosis lung cancer is raised by combined assaying with serum CEA, CA153, SCC and CY211, so as in early lung cancer. We suggest that combined assay with CA153+CY211 is better.
出处
《中国临床医学》
2002年第3期240-242,共3页
Chinese Journal of Clinical Medicine
